Recent developments highlight regulatory progress, clinical trial advancements, and financing activities supporting Anteris Technologies' DurAVR transcatheter heart valve.

• Anteris received German regulatory clearance for the PARADIGM DurAVR trial, supporting its global clinical development efforts [N1].
• Barclays initiated coverage of Anteris Technologies Global with an equal-weight rating, indicating analyst interest [N2].
• The company advanced DurAVR toward commercialization and expanded U.S. recruitment in the PARADIGM trial [N3].
• Anteris treated the first U.S. patients in the global pivotal PARADIGM trial of DurAVR THV as of May 2026 [N4].
• Wells Fargo initiated coverage with an overweight recommendation, reflecting positive analyst engagement [N5].
• Anteris completed a $200 million public offering and announced a Medtronic private placement up to $90 million, strengthening its financial position [N6][N7].
• The company was among the most active pre-market stocks on January 21, 2026, reflecting market interest [N8].

The company has made significant progress in advancing its DurAVR transcatheter heart valve through pivotal clinical trials with FDA and German regulatory approvals. Expansion of U.S. patient recruitment and treatment in the PARADIGM trial demonstrate clinical momentum. Strong liquidity from recent public offerings and private placements supports ongoing development and commercialization efforts. Analyst coverage initiation by major firms indicates growing market interest.

Anteris Technologies continues to report net losses and negative earnings per share, reflecting ongoing development costs and limited revenue generation. The company remains dependent on successful clinical trial outcomes and regulatory approvals for commercialization. Market competition in the transcatheter heart valve space is intense, and delays or setbacks in trials or approvals could impact business progress. The company's financial position, while currently strong in liquidity, requires continued capital access to sustain operations.

Anteris Technologies' moat is centered on its proprietary DurAVR transcatheter heart valve technology and its clinical development progress, including regulatory approvals and ongoing pivotal trials. The company's partnerships, such as the private placement with Medtronic, and its capital raising efforts provide financial resources to support commercialization. The regulatory clearances and clinical trial advancements create barriers to entry for competitors in the transcatheter heart valve market segment.

• Clinical Trial and Regulatory Risk: The success of Anteris Technologies depends heavily on the outcomes of the PARADIGM pivotal trial and regulatory approvals. Any delays, adverse results, or regulatory setbacks could materially affect the company's ability to commercialize DurAVR.
• Financial Risk: The company has reported net losses and negative EPS, indicating ongoing expenses exceeding revenues. Continued access to capital markets and partnerships is critical to fund development and commercialization activities.
• Market Competition: The transcatheter heart valve market is competitive with established players. Anteris faces risks from competitors with more established products and greater resources.

• Anteris Technologies Global Corp. is a medical technology company focused on developing and commercializing the DurAVR transcatheter heart valve (THV).
• The company is conducting the global pivotal PARADIGM clinical trial for DurAVR, with regulatory approvals including FDA approval and German regulatory clearance for the trial.
• The PARADIGM trial has expanded U.S. patient recruitment and treated its first U.S. patients as of May 2026.
• Anteris has advanced DurAVR toward commercialization.
• The company completed a $200 million public offering and announced a private placement with Medtronic up to $90 million in January 2026.
• Anteris Technologies is listed on The Nasdaq Global Market under the ticker AVR.
• As of June 30, 2026, the company had $249.9 million in cash and cash equivalents and current assets of $260.7 million, with current liabilities of $18.36 million, resulting in a strong current ratio of 14.2 and a cash ratio of 13.61.
• The company reported a net loss of $29.1 million and basic and diluted EPS of -$0.30 for the quarter ended June 30, 2026.
• The number of shares outstanding was approximately 97.5 million as of August 10, 2026.
• The company is incorporated in Delaware and headquartered in Toowong, Queensland, Australia.
• Anteris Technologies is classified as a smaller reporting company and an emerging growth company.
• The company has received multiple analyst initiations and coverage, including from Wells Fargo and Barclays.
• The latest SEC filings include an amended 10-K for fiscal year ended December 31, 2025, and an amended 10-Q for the quarter ended June 30, 2026, both filed in November 2026.